Cellular Senescence and Obesity
Cellular senescence is the accumulation of cells that stop dividing but stay alive and leak inflammatory signals - one way obesity behaves like accelerated ageing.
Plain English
Patient-Friendly Explanation
Most cells in the body have a limit on how many times they can divide. When a cell reaches that limit, or when its DNA is damaged, it can enter a state called senescence. A senescent cell stops dividing, but it does not disappear - it stays in the tissue and releases a steady stream of inflammatory signalling molecules that damage and age the cells around it. This is normal with age, but it happens faster in obesity. Fat tissue from people with obesity contains more of these cells, along with the liver, pancreas and brain, and that burden is one reason obesity behaves like accelerated ageing: more inflammation, more insulin resistance, more fat in the liver. Researchers can identify these cells by markers such as p16 and p21. Experimental drugs called senolytics, which clear senescent cells, improve glucose handling and reduce inflammation in obese and aged mice, and human trials are still early and small. No anti-ageing pill is approved, and the interventions with real evidence behind them are ordinary: losing excess weight, exercising, sleeping properly, and treating blood pressure, glucose and cholesterol.
Medical
Clinical Definition
Cellular senescence was described by Hayflick as replicative exhaustion and is now characterised by irreversible cell-cycle arrest with a viable, metabolically active phenotype. Hallmarks include upregulation of cyclin-dependent kinase inhibitors p16INK4a and p21CIP1, senescence-associated beta-gal (SA-beta-gal) activity, telomere attrition, persistent DNA damage responses and chromatin remodelling, accompanied by the senescence-associated secretory phenotype - a secretome containing interleukin-6, tumour necrosis factor alpha, monocyte chemoattractant protein-1 and matrix metalloproteinases that propagates low-grade inflammation into neighbouring tissue. Senescent cell burden increases in obesity across adipose tissue, liver, pancreas and brain, and in adipose tissue the process is driven by hypertrophic adipocyte stress, oxidative and endoplasmic reticulum stress and p53/p21 and p16 pathway activation, with senescence contributing to impaired adipogenesis, adipose tissue dysfunction, insulin resistance and metabolic dysfunction-associated steatotic liver disease. Because senescent cells accumulate in both ageing and obesity, obesity is described as a state of accelerated biological ageing. In preclinical models, senolytic agents such as the dasatinib and quercetin combination, navitoclax and fisetin selectively clear senescent cells and improve glucose tolerance, reduce the secretory phenotype and extend healthspan in obese and aged mice; human data remain early-phase, predominantly safety and feasibility, and no senolytic is approved for any indication. Weight loss, caloric restriction and habitual exercise reduce senescence and inflammatory markers in human studies, although marker specificity is a known limitation because senescence signatures overlap with quiescence, DNA-damage responses and other stress states.
Key Insight
Why It Matters
Obesity and ageing wind up the same inflammatory machinery, which is why a 40-year-old with excess fat can carry the metabolic profile of someone considerably older - and why the fix is still weight, movement and sleep rather than a supplement.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
